Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Oct;32(5):410-425.
Epub 2019 Sep 11.

Clinical practice update of antifungal prophylaxis in immunocompromised children

J T Ramos  1 , C A Romero, S Belda, F J Candel, B Carazo Gallego, A Fernández-Polo, L Ferreras Antolín, C Garrido Colino, M L Navarro, O Nef, P Olbright, E Rincón-López, J Ruiz Contreras, P Soler-Palacín; Fungal Infection Study Group of Spanish Society of Paediatric Infectious Disease (SEIP); Traslational Research Network in Pediatric Infectious Diseases (RITIP).
Affiliations
Review

Clinical practice update of antifungal prophylaxis in immunocompromised children

J T Ramos et al. Rev Esp Quimioter. 2019 Oct.

Abstract
in English, Spanish

Due to the rise in the number and types of immunosuppressed patients, invasive fungal infections (IFI) are an increasing and major cause of morbidity and mortality in immunocompromised adults and children. There is a broad group of pediatric patients at risk for IFI in whom primary and/or secondary antifungal prophylaxis (AFP) should be considered despite scant evidence. Pediatric groups at risk for IFI includes extremely premature infants in some settings, while in high-risk children with cancer receiving chemotherapy or undergoing haematopoietic stem cell transplantation (HCT), AFP against yeast and moulds is usually recommended. For solid organ transplanted, children, prophylaxis depends on the type of transplant and associated risk factors. In children with primary or acquired immunodeficiency such as HIV or long-term immunosuppressive treatment, AFP depends on the type of immunodeficiency and the degree of immunosuppression. Chronic granulomatous disease is associated with a particular high-risk of IFI and anti-mould prophylaxis is always indicated. In contrast, AFP is not generally recommended in children with long stay in intensive care units. The choice of AFP is limited by the approval of antifungal agents in different age groups and by their pharmacokinetics characteristics. This document aims to review current available information on AFP in children and to provide a comprehensive proposal for each type of patient.

Las infecciones fúngicas invasoras (IFI) constituyen un problema creciente en adultos y niños inmunodeprimidos, acompañándose de una elevada morbimortalidad. El número de niños inmunodeprimidos va en aumento. Los grupos de riesgo de IFI en pediatría incluyen a los grandes prematuros, que se benefician de profilaxis con fluconazol, pacientes hemato-oncológicos sometidos a quimioterapia o trasplante de precursores hematopoyéticos con neutropenias prolongadas, en quienes la profilaxis frente a hongos filamentosos suele recomendarse en situaciones de alto riesgo. En niños sometidos a trasplante de órgano sólido, la profilaxis depende del tipo de trasplante y factores de riesgo asociados. En pacientes con inmunodeficiencias primarias o adquiridas como la infección VIH o tratamiento inmunosupresor prolongado, la profilaxis antifúngica dependerá del tipo de inmunodeficiencia primaria y del grado de inmunosupresión. La enfermedad granulomatosa crónica tiene riesgo particularmente elevado de IFI y requiere siempre profilaxis frente a hongos filamentosos. En cambio, en niños con ingresos prolongados en cuidados intensivos la profilaxis frente a IFI habitualmente no está indicada. El tipo de profilaxis está limitado por la diferente aprobación de antifún-gicos a distintas edades. Este documento pretende revisar la información actual disponible respecto a profilaxis antifúngica en niños, con propuesta para la estrategia más apropiada en cada tipo de paciente.

PubMed Disclaimer

References

    1. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky Zeichner et al. . Clinical practice guideline for the mana,ge-ment of Candidiasis: 2016 update by the Infectious Diseases Socie-ty of America. Clin Infect Dis.2016;62: e1–50.19. DOI: 10.1093/cid/civ1194 - DOI - PMC - PubMed
    1. Warris A, Lehrnbecher T, Roilides E, Castagnola E, Brüggemann RJM, Groll AH. ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children. Clin Microbiol Infect. 2019: S1198-743X(19)30282-4. DOI: 10.1016/j.cmi.2019.05.019. - DOI - PubMed
    1. Benjamin DK Jr, Poole C, Steinbach WJ, Rowen JL, Walsh TJ. Ne-onatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003; 112:634-640. DOI. 10.1542/peds.112.3.634 - DOI - PubMed
    1. Zaoutis TE, Prasad PA, Localio AR, Coffin SE, Bell LM, Walsh TJ, Gross R. Risk factors and predictors for candidemia in pediatric in-tensive care unit patients: implications for prevention. Clin Infect Dis 2010; 51:e38-e45. DOI: 10.1086/655698 - DOI - PMC - PubMed
    1. Aguado JM, Ruiz I, Muñoz P, Mensa J, Almirante B, Vázquez L, Ro-vira M, et al. por el Grupo de Estudio de Micología Médica de la SEIMC (GEMICOMED) . Recomendaciones sobre el Tratamiento de la Candidiasis Invasiva y Otras Infecciones por Levaduras de la Socie-dad Española de Microbiología Clínica y Enfermedades Infecciosas (SEIMC). Actualización 2010. Enferm Infecc Microbiol Clin. 2011; 29:345-61. DOI: 10.1016/j.eimc.2011.01.008 - DOI - PubMed

MeSH terms

Substances